Table 1.
Demographic and clinical characteristics of samples collected from SARS-CoV-2 infected cohort (n = 127), vaccinated cohort (n = 121), and controls (n = 70).
| SARS-CoV-2 infected patients | COVID-19 vaccinated individuals | Pre-pandemic controls | |
|---|---|---|---|
| Median age in years (IQR) | 35.0 (27.0–43.5) | 35.0 (25.5–44.5) | 43.0 (37.0–51.0) |
| Gender | |||
| Female | 20 (12.5) | 68 (41.7) | 3 (4.3) |
| Male | 137 (85.6) | 82 (50.3) | 67 (95.7) |
| Not determined | 3 (1.9) | 13 (8.0) | – |
| Disease status | |||
| Symptomatic | 56 (35.0) | ||
| Asymptomatic | 90 (56.3) | ||
| Not determined | 14 (8.8) | ||
| Vaccine type | |||
| Pfizer (BNT162b2) | 97 (80.2) | ||
| Moderna (mRNA-1273) | 24 (19.8) | ||
| Median days of sampling (IQR)a | 46 (20–163) | 63 (35–114) | |
| Total | 160 | 163 | 70 |
aMedian days of sampling post symptoms onset or RT-PCR positive test for SARS-CoV-2 infected cohort or post-second dose administration for the vaccinated cohort. SARS-CoV-2: severe acute respiratory syndrome virus 2, COVID-19: Coronavirus Disease 2019.
IQR interquartile range.